{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T05:08:29Z","timestamp":1777871309693,"version":"3.51.4"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004423","name":"WHO","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001773","name":"University of New South Wales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001773","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032626","name":"Unitaid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032626","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005294","name":"Massachusetts General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005294","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007229","name":"Harvard University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007229","id-type":"DOI","asserted-by":"publisher"}]},{"name":"TREAT Asia"},{"DOI":"10.13039\/100001117","name":"The Foundation for AIDS Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001117","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University International Postgraduate","award":["RSRE7061"],"award-info":[{"award-number":["RSRE7061"]}]},{"DOI":"10.13039\/501100025520","name":"Medical Research Future Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100025520","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Genomics Health Futures Mission\u2014Pathogens Genomics Grant Opportunity","award":["FSPGN000047"],"award-info":[{"award-number":["FSPGN000047"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>D\u00b2EFT (Dolutegravir and Darunavir Evaluation in Adults Failing Therapy) was a phase 3b\/4 randomized clinical trial designed to assess second-line treatment options systematically. This substudy evaluated the distribution of drug resistance mutations (DRMs) before treatment randomization in individuals failing first-line therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From a total of 826 participants across 14 countries, 727 sequences that covered the PR-RT-INT (700), PR-RT (24), and RT (3) regions were analyzed for drug resistance. Sequences were submitted to the Stanford HIV drug resistance database to detect DRMs and assign subtypes. By adjusting for country and antiretroviral therapy regimen, we assessed the association between DRMs and country and reported DRMs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Subtype C of human immunodeficiency virus type 1 (HIV-1) accounted for most (59.3%) infections. There were extraordinarily high rates of high-level resistance to lamivudine and emtricitabine (both at 88.3%) and for efavirenz and nevirapine (92.8% and 96.8%, respectively). On average, nucleoside reverse transcriptase inhibitor mutations had the highest occurrence across countries with M184V\/I detected in 86.2% of the samples, while the highest proportion of nonnucleoside reverse transcriptase inhibitor mutations was K103N at 57.8%. K103N had an increased likelihood of occurrence in African and South American countries (P &amp;lt; .05). Participants with prior exposure to a zidovudine-containing regimen had an increased likelihood of T215F\/Y mutations (6.80 [2.59\u201317.86]), while those with nevirapine\/rilpivirine exposure had a decreased likelihood of K103N mutations (0.29 [0.15\u20130.56]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The regional specificity of mutations underscores the dynamic nature of HIV-1 drug resistance patterns and the importance of monitoring and understanding local mutation profiles.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaf739","type":"journal-article","created":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T12:46:23Z","timestamp":1767271583000},"page":"e693-e704","source":"Crossref","is-referenced-by-count":0,"title":["Regional Variations of Rates and Determinants of Drug Resistance Mutations in People Failing First-line Therapy for HIV-1: A Substudy from the D2EFT Phase 3b\/4 Clinical Trial"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1158-7922","authenticated-orcid":false,"given":"Billal Musah","family":"Obeng","sequence":"first","affiliation":[{"name":"The Kirby Institute, University of New South Wales , Sydney, New South Wales ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolie","family":"Hutchinson","sequence":"additional","affiliation":[{"name":"The Kirby Institute, University of New South Wales , Sydney, New South Wales ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ansari","family":"Shaik","sequence":"additional","affiliation":[{"name":"The Kirby Institute, University of New South Wales , Sydney, New South Wales ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9501-5827","authenticated-orcid":false,"given":"Ploenchan","family":"Chetchotisakd","sequence":"additional","affiliation":[{"name":"Srinagarind Hospital, Khon Kaen University , Khon Kaen ,","place":["Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iskandar","family":"Azwa","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, Faculty of Medicine, Universiti Malaya , Kuala Lumpur ,","place":["Malaysia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6920-7235","authenticated-orcid":false,"given":"Wahyu Nawang","family":"Wulan","sequence":"additional","affiliation":[{"name":"Reference laboratory, Indonesia Research Partnership on Infectious Diseases (INA-RESPOND) , Jakarta ,","place":["Indonesia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2252-5731","authenticated-orcid":false,"given":"Nagalingeswaran","family":"Kumarasamy","sequence":"additional","affiliation":[{"name":"VHS Infectious Diseases Medical Centre, CART-Clinical Research Site Chennai , Chennai ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo","family":"Wolff","sequence":"additional","affiliation":[{"name":"Fundacion Arriaran , Hospital San Borja Arriar\u00e1n, Santiago ,","place":["Chile"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Bruguera","sequence":"additional","affiliation":[{"name":"Emerging Diseases Research Unit, Hospital J.M. Ramos Mej\u00eda , Buenos Aires ,","place":["Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo","family":"Losso","sequence":"additional","affiliation":[{"name":"Emerging Diseases Research Unit, Hospital J.M. Ramos Mej\u00eda , Buenos Aires ,","place":["Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1565-4704","authenticated-orcid":false,"given":"Richard","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Desmond Tutu Health Foundation , Cape Town ,","place":["South Africa"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariama Sadjo","family":"Diallo","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences and Techniques, Gamal Abdel Nasser University and Donka Hospital ,","place":["Guinea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2528-8082","authenticated-orcid":false,"given":"Nnakelu","family":"Eriobu","sequence":"additional","affiliation":[{"name":"International Research Center of Excellence, Institute of Human Virology Nigeria , Abuja ,","place":["Nigeria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Godfrey","family":"Musoro","sequence":"additional","affiliation":[{"name":"Clinical Research Centre, University of Zimbabwe , Harare ,","place":["Zimbabwe"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9736-0608","authenticated-orcid":false,"given":"July","family":"Kumalawati","sequence":"additional","affiliation":[{"name":"Department of Pathology, Dr Cipto Mangunkusumo Hospital , Jakarta ,","place":["Indonesia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abba","family":"Badamasi","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, National Hospital Abuja , Abuja ,","place":["Nigeria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munawaroh","family":"Fitriah","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Dr Soetomo Hospital , Surabaya ,","place":["Indonesia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deshinta Putri","family":"Mulya","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dr Sardjito Hospital , Yogyakarta ,","place":["Indonesia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Law","sequence":"additional","affiliation":[{"name":"The Kirby Institute, University of New South Wales , Sydney, New South Wales ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1048-6396","authenticated-orcid":false,"given":"Gail","family":"Matthews","sequence":"additional","affiliation":[{"name":"The Kirby Institute, University of New South Wales , Sydney, New South Wales ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Di Giallonardo","sequence":"additional","affiliation":[{"name":"The Kirby Institute, University of New South Wales , Sydney, New South Wales ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0009-3337","authenticated-orcid":false,"given":"Anthony Dominic","family":"Kelleher","sequence":"additional","affiliation":[{"name":"The Kirby Institute, University of New South Wales , Sydney, New South Wales ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Dolutegravir and Darunavir Evaluation in Adults Failing Therapy (D2EFT) Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Billal Musah","family":"Obeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolie","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ansari","family":"Shaik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ploenchan","family":"Chetchotisakd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iskandar","family":"Azwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wahyu Nawang","family":"Wulan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagalingeswaran","family":"Kumarasamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Bruguera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo","family":"Losso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariama Sadjo","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nnakelu","family":"Eriobu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Godfrey","family":"Musoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"July","family":"Kumalawati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abba","family":"Badamasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munawaroh","family":"Fitriah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deshinta Putri","family":"Mulya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Law","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gail","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Di Giallonardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony Dominic","family":"Kelleher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie Yuek","family":"Kee Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"key":"2026043013115185900_ciaf739-B1","volume-title":"Global HIV and AIDS statistics\u2014fact sheet","author":"Joint United Nations Programme on HIV\/AIDS (UNAIDS)","year":"2021"},{"key":"2026043013115185900_ciaf739-B2","volume-title":"Global HIV programme","author":"World Health Organization (WHO)","year":"2024"},{"key":"2026043013115185900_ciaf739-B3","doi-asserted-by":"crossref","first-page":"S203","DOI":"10.1097\/QAD.0000000000002321","article-title":"HIV estimates through 2018: data for decision-making","volume":"33","author":"Mahy","year":"2019","journal-title":"AIDS"},{"issue":"Suppl 2","key":"2026043013115185900_ciaf739-B4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/135965350801302S07","article-title":"World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites","volume":"13","author":"Jordan","year":"2008","journal-title":"Antivir Ther"},{"key":"2026043013115185900_ciaf739-B5","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1097\/QAI.0000000000001285","article-title":"HIV drug resistance mutations in non-B subtypes after prolonged virological failure on NNRTI-based first-line regimens in sub-Saharan Africa","volume":"75","author":"Kityo","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026043013115185900_ciaf739-B6","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","article-title":"HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis","volume":"18","author":"Gupta","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2026043013115185900_ciaf739-B7","volume-title":"HIV drug resistance report 2019","author":"World Health Organization (WHO)","year":"2019"},{"key":"2026043013115185900_ciaf739-B8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ebiom.2017.03.024","article-title":"Mutational correlates of virological failure in individuals receiving a WHO-recommended tenofovir-containing first-line regimen: an international collaboration","volume":"18","author":"Rhee","year":"2017","journal-title":"EBioMedicine"},{"key":"2026043013115185900_ciaf739-B9","doi-asserted-by":"crossref","first-page":"100238","DOI":"10.1016\/j.eclinm.2019.100238","article-title":"Trend of HIV-1 drug resistance in China: a systematic review and meta-analysis of data accumulated over 17 years (2001\u20132017)","volume":"18","author":"Zuo","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2026043013115185900_ciaf739-B10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13756-021-00931-w","article-title":"Surveillance of antimicrobial resistance in low-and middle-income countries: a scattered picture","volume":"10","author":"Iskandar","year":"2021","journal-title":"Antimicrob Resist Infect Control"},{"key":"2026043013115185900_ciaf739-B11","doi-asserted-by":"crossref","first-page":"e436","DOI":"10.1016\/S2352-3018(24)00089-4","article-title":"Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D\u00b2EFT): an open-label, randomised, phase 3b\/4 trial","volume":"11","author":"D2EFT Study Group","year":"2024","journal-title":"Lancet HIV"},{"key":"2026043013115185900_ciaf739-B12","doi-asserted-by":"crossref","first-page":"e1001810","DOI":"10.1371\/journal.pmed.1001810","article-title":"Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient-and sequence-level meta-analysis","volume":"12","author":"Rhee","year":"2015","journal-title":"PLoS Med"},{"key":"2026043013115185900_ciaf739-B13","volume-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach","author":"World Health Organization (WHO)","year":"2016"},{"key":"2026043013115185900_ciaf739-B14","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/jac\/dky003","article-title":"HIV-1 genotypic resistance testing using the Vela automated next-generation sequencing platform","volume":"73","author":"Raymond","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2026043013115185900_ciaf739-B15","doi-asserted-by":"crossref","first-page":"107986","DOI":"10.1016\/j.isci.2023.107986","article-title":"Development of a multiassay algorithm (MAA) to identify recent HIV infection in newly diagnosed individuals in Indonesia","volume":"26","author":"Wulan","year":"2023","journal-title":"iScience"},{"key":"2026043013115185900_ciaf739-B16","author":"Geneious Prime software"},{"key":"2026043013115185900_ciaf739-B17","first-page":"559","article-title":"2022 update of the drug resistance mutations in HIV-1","volume":"30","author":"Wensing","year":"2022","journal-title":"Top Antivir Med"},{"key":"2026043013115185900_ciaf739-B18","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/molbev\/msu300","article-title":"IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies","volume":"32","author":"Nguyen","year":"2015","journal-title":"Mol Biol Evol"},{"key":"2026043013115185900_ciaf739-B19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jclinepi.2019.09.021","article-title":"Multiple uses of forest plots in presenting analysis results in health research: a tutorial","volume":"117","author":"Li","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"2026043013115185900_ciaf739-B20","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S2352-3018(14)00061-7","article-title":"Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis","volume":"2","author":"Boyd","year":"2015","journal-title":"Lancet HIV"},{"key":"2026043013115185900_ciaf739-B21","doi-asserted-by":"crossref","first-page":"136","DOI":"10.24875\/AIDSRev.23000002","article-title":"The impact of the M184V resistance mutation on treatment outcomes in patients with HIV infection: a systematic review and meta-analysis","volume":"25","author":"Kandeel","year":"2023","journal-title":"AIDS Rev"},{"key":"2026043013115185900_ciaf739-B22","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1128\/AAC.05487-11","article-title":"Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility","volume":"56","author":"Melikian","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026043013115185900_ciaf739-B23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1310\/hct1202-61","article-title":"Reduced emergence of the M184V\/I resistance mutation when antiretroviral-naive subjects use emtricitabine versus lamivudine in regimens composed of two NRTIs plus the NNRTI efavirenz","volume":"12","author":"McColl","year":"2011","journal-title":"HIV Clin Trials"},{"key":"2026043013115185900_ciaf739-B24","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/hiv.12829","article-title":"Continuation of emtricitabine\/lamivudine within combination antiretroviral therapy following detection of the M184V\/I HIV-1 resistance mutation","volume":"21","author":"Stirrup","year":"2020","journal-title":"HIV Med"},{"key":"2026043013115185900_ciaf739-B25","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1097\/QAD.0000000000001191","article-title":"The M184I\/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir","volume":"30","author":"Oliveira","year":"2016","journal-title":"AIDS"},{"key":"2026043013115185900_ciaf739-B26","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3390\/v15071416","article-title":"Added value of next generation sequencing in characterizing the evolution of HIV-1 drug resistance in Kenyan youth","volume":"15","author":"Novitsky","year":"2023","journal-title":"Viruses"},{"key":"2026043013115185900_ciaf739-B27","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jac\/dkt316","article-title":"Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing","volume":"69","author":"Melikian","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2026043013115185900_ciaf739-B28","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/s41591-023-02763-0","article-title":"HIV drug resistance to integrase inhibitors in low-and middle-income countries","volume":"30","author":"Fokam","year":"2024","journal-title":"Nat Med"},{"key":"2026043013115185900_ciaf739-B29","volume-title":"Fact sheet: HIV drug resistance","author":"World Health Organization (WHO)","year":"2024"},{"key":"2026043013115185900_ciaf739-B30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3851\/IMP2437","article-title":"Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review","volume":"18","author":"Stadeli","year":"2013","journal-title":"Antivir Ther"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf739\/66225882\/ciaf739.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/4\/e693\/66225882\/ciaf739.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/4\/e693\/66225882\/ciaf739.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:12:01Z","timestamp":1777569121000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/4\/e693\/8413189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,1,3]]},"published-print":{"date-parts":[[2026,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf739","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,15]]},"published":{"date-parts":[[2026,1,3]]}}}